International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial
Key facts
- Who runs it
- NYU Langone Health
- Where
- New York, United StatesSee the siteAlso in 5 other countries, 5 sites
- Trial code
- Status
- Suspended
- Phase
- Phase 3
- People taking part
- 1,200 people, planned
- Starts
- Dec 2026
- Expected to end
- Dec 2032
- Type of study
- Interventional, 3 groups
- Treatments tested
- Guideline-directed medical therapy (GDMT)
- Coronary artery bypass grafting (CABG)
- Percutaneous coronary intervention (PCI).
- Record updated
- 5 June 2026
- Why it stopped
- Study temporarily paused.
Who can take part
- Age
- 55 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Left ventricular ejection fraction (LVEF) ≤ 40% within prior 6 months (any local measurement, made within the past 6 months using echocardiography, multigated acquisition (MUGA), computed tomography (CT) scanning, magnetic resonance imaging (MRI), or ventricular angiography is acceptable, provided no subsequent measurement above 40%)
- Participants with multivessel CAD (defined as severe 3 vessel disease or 2 vessel disease including left anterior descending (LAD) artery disease) on coronary CT angiography (CCTA) or invasive coronary angiography
- CAD amenable to either PCI or CABG as determined by the local heart team
- Participant is willing to comply with all aspects of the protocol, including adherence to the assigned strategy, medical therapy and follow-up visits
- Participant is able and willing to give written informed consent
Who cannot take part
- Decompensated heart failure or cardiogenic shock in the past 48 hours prior to randomization
- Concomitant significant valvular heart disease requiring surgery
- Prior cardiac surgery
- Dementia with loss of capacity to consent (clinically evident or previously diagnosed)
- Stroke within the previous 6 months or spontaneous intracranial hemorrhage at any time
- History of noncompliance with medical therapy
- Life expectancy less than the duration of the trial due to non-cardiovascular comorbidity
- Pregnancy (known to be pregnant; to be confirmed before randomization, if applicable)
Where in United States
Also in 5 other countries, 5 sites
- NYU Langone HealthNew York, United States
About the trial
What the trial wants to find out
The ISCHEMIA-HF trial will randomize participants with multivessel coronary artery disease (CAD) with ejection fraction (EF) ≤40% in a 1:2:2 fashion to guideline-directed medical therapy (GDMT):coronary artery bypass grafting (CABG):percutaneous coronary intervention (PCI).
The 3 groups in the trial
- GDMTTreatment being tested
Participants with multivessel coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF) who are assigned to receive GDMT.
Treatment: Guideline-directed medical therapy (GDMT)
- CABGTreatment being tested
Participants with multivessel coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF) who are assigned to receive CABG.
Treatment: Coronary artery bypass grafting (CABG)
- PCITreatment being tested
Participants with multivessel coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF) who are assigned to receive PCI.
Treatment: Percutaneous coronary intervention (PCI).
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ISCHEMIA-LVD: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial
- Record updated
- 5 June 2026